These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19637976)

  • 1. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.
    Cakir M; Grossman AB
    Expert Opin Ther Targets; 2009 Sep; 13(9):1121-34. PubMed ID: 19637976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mTOR signaling in lung cancer.
    Marinov M; Fischer B; Arcaro A
    Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
    Garcia-Echeverria C; Sellers WR
    Oncogene; 2008 Sep; 27(41):5511-26. PubMed ID: 18794885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.
    Lim KH; Counter CM
    Cancer Cell; 2005 Nov; 8(5):381-92. PubMed ID: 16286246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.
    Lin Y; Jiang X; Shen Y; Li M; Ma H; Xing M; Lu Y
    Endocr Relat Cancer; 2009 Mar; 16(1):301-10. PubMed ID: 18852163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells.
    Dai J; Peng L; Fan K; Wang H; Wei R; Ji G; Cai J; Lu B; Li B; Zhang D; Kang Y; Tan M; Qian W; Guo Y
    Oncogene; 2009 Sep; 28(38):3412-22. PubMed ID: 19597469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Raf/MEK/ERK pathway in pituitary adenomas.
    Suojun Z; Feng W; Dongsheng G; Ting L
    Eur J Cancer; 2012 Feb; 48(3):389-95. PubMed ID: 22119203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
    Lackner MR
    Expert Rev Mol Diagn; 2010 Jan; 10(1):75-87. PubMed ID: 20014924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
    Porta C; Figlin RA
    J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein interaction data set highlighted with human Ras-MAPK/PI3K signaling pathways.
    Wang J; Yuan Y; Zhou Y; Guo L; Zhang L; Kuai X; Deng B; Pan Z; Li D; He F
    J Proteome Res; 2008 Sep; 7(9):3879-89. PubMed ID: 18624398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas.
    Monsalves E; Juraschka K; Tateno T; Agnihotri S; Asa SL; Ezzat S; Zadeh G
    Endocr Relat Cancer; 2014 Aug; 21(4):R331-44. PubMed ID: 25052915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Signal transduction by protein tyrosine kinases and antitumor agents].
    Mao YJ; Li HH; Li JF; Shen JS
    Yao Xue Xue Bao; 2008 Apr; 43(4):323-34. PubMed ID: 18664191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer.
    Assinder SJ; Dong Q; Kovacevic Z; Richardson DR
    Biochem J; 2009 Jan; 417(2):411-21. PubMed ID: 19099539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis.
    Boikos SA; Stratakis CA
    Hum Mol Genet; 2007 Apr; 16 Spec No 1():R80-7. PubMed ID: 17613552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells.
    Zhou YJ; Yang HW; Wang XG; Zhang H
    Life Sci; 2009 Nov; 85(19-20):670-7. PubMed ID: 19778541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and biological characterization of tumor-associated mutations of p110alpha.
    Denley A; Gymnopoulos M; Hart JR; Jiang H; Zhao L; Vogt PK
    Methods Enzymol; 2008; 438():291-305. PubMed ID: 18413256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical target promiscuity: lessons from ras molecular trials.
    Rengan R; Cengel KA; Hahn SM
    Cancer Metastasis Rev; 2008 Sep; 27(3):403-14. PubMed ID: 18461427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partially purified Curcuma longa inhibits alpha-melanocyte-stimulating hormone-stimulated melanogenesis through extracellular signal-regulated kinase or Akt activation-mediated signalling in B16F10 cells.
    Jang JY; Lee JH; Jeong SY; Chung KT; Choi YH; Choi BT
    Exp Dermatol; 2009 Aug; 18(8):689-94. PubMed ID: 19469902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.